Apotex receives first FDA tentative approval for semaglutide injection ANDA developed with Orbicular, as global generic launches accelerate and India already sees marketed versions.
Written By: Dillikumari A, BPharm
Reviewed By: Pharmacally Editorial Team
Apotex Corp. announced it has received the first U.S. Food and Drug Administration tentative approval for its Abbreviated New Drug Application (ANDA) for semaglutide injection, expanding access to complex peptide therapies in the United States. The tentative approval confirms that the application meets regulatory standards but remains subject to final approval once exclusivity and patent considerations are resolved.
Because the ANDA references Ozempic, Apotex’s semaglutide injection is expected to align with the diabetes indication of the reference product, though final labeling will be confirmed at the time of full approval.
The semaglutide injection program was developed through a strategic partnership with Orbicular Pharmaceutical Technologies. The companies said they used advanced testing and a well-controlled manufacturing process to show their semaglutide injection closely matches the reference product.
According to Barry Fishman, Chief Corporate Development Officer at Apotex, the milestone reflects the impact of collaboration and the alignment of complementary capabilities. He indicated that the partnership combined scientific expertise and execution discipline to advance a technically challenging generic program.
S. Mohan, Managing Director of Orbicular Pharmaceutical Technologies, emphasized that achieving equivalence for complex peptide products requires rigorous analytical precision and disciplined development. He noted that Orbicular’s development support alongside Apotex’s regulatory leadership played a central role in obtaining tentative approval.
The tentative approval highlights Apotex’s global development model for complex generics designed to meet stringent regulatory requirements. Once eligible for final approval, the semaglutide injection is expected to expand availability in a therapeutic area where affordability and supply remain important considerations.
The launch of generic semaglutide is gaining momentum globally as manufacturers move to enter the market following patent expirations and regulatory pathways for complex peptide generics. Several companies are introducing lower-cost versions to improve access to GLP-1–based therapies. Like in India, generic semaglutide has already been introduced, with companies such as Sun pharma, Biocon and Dr. Reddy’s Laboratories and many others launching their versions, underscoring how competition is beginning to expand availability and potentially reduce costs in high-demand metabolic therapy segments.
Reference
Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular, 10 April 2026, https://www.apotex.com/global/news/news-release/2026/04/10/apotex-receives-first-us-fda-tentative-approval-for-a-generic-version-of-ozempic-semaglutide-injection-in-partnership-with-orbicular
About the Writer
DilliKumari is a Pharmacy graduate based in Ariyur, Puducherry. She has a strong interest in pharmacovigilance and is particularly drawn to data analysis within the healthcare field. She is known for her willingness to learn and continuously improve, with a keen attention to detail that sometimes leads her to spend extra time refining her work.
